

**FOR IMMEDIATE RELEASE**

**License and Supply Agreement signed to market  
Leuprolide in China, Hong Kong and Macau**

(Hong Kong 14<sup>th</sup> December 2012) – Lee's Pharmaceutical Holdings Limited (Main Board Stock: 0950: Website: [www.leespharm.com](http://www.leespharm.com)) today announced the signing of a License and Supply Agreement with GP PHARM S.A., Spain for obtaining the Technological Transfer for the registration, production, distribution and marketing of Leuprolide, throughout China, Hong Kong and Macau.

Under the terms of agreement, GP Pharm agrees to manufacture for Lee's the finished product ready for administration (1 month formulation–3.75mg and 3 month depot); and/or supplies the bulk product containing Leuprolide acetate (in the form of microcapsules) for the preparation of finished products.

Leuprolide acetate, belongs to a group of drugs called agonists of luteinising hormone-releasing hormone (LHRH), which are drugs that reduce testosterone (sex hormone). Leuprolide acetate is a hormonal androgen deprivation therapy to prevent tumor growth in patients with advanced prostate cancer. Leuprolide 1 month is the first controlled-release drug system entirely developed by GP Pharm and indicated for the treatment of advance prostate cancer. It has been approved in 23 countries in the European Union, including Spain, Germany, the UK and Italy, etc. It is expected to be filed in the USA shortly and in a number of other countries worldwide. Other presentations of Leuprolide are currently under development by GP Pharm, mainly within the framework of therapeutic areas for oncology (prostate cancer, ovarian cancer, breast cancer, carcinoid syndrome), central nervous system and cardiovascular diseases.

“We are honored and excited to have the opportunity to work with a great company like GP Pharm and its great product Leuprolide. This agreement reflects again the Group's effort in building an oncology franchise,” commented by Dr. Benjamin Li, the Chief Executive Officer of Lee's Pharmaceutical Holdings Limited. “It is the intention of the Group to start the registration process of Leuprolide firstly and launch the product soonest.”

## FOR IMMEDIATE RELEASE

### **Advanced Prostate Cancer**

Prostate cancer normally develops within the peripheral area of the prostate gland and this initially small area of cancerous tissue cannot be felt on a digital rectal examination (DRE) but is often picked up through a PSA test or an ultrasound examination. As prostate cancer cells require male hormones (such as testosterone) to grow, the main form of treatment for advanced prostate cancer is hormone treatment to reduce the production of testosterone. Hormone therapy may include the use of drugs to reduce testosterone levels in the body or to block the action of testosterone and other male hormones. Treatment options will also include the removal of the testicles (orchiectomy) which produce 95% of the testosterone found in the body. In some cases of Stage IV cancer hormone therapy may not be effective, or may have only limited results, and patients may require systematic radiation therapy or chemotherapy.

### **About GP Pharm**

**GP Pharm**, is located in Barcelona (Spain). Their activities are focused on research, development, production and marketing of injectable products within Urology and Oncology fields, some of them based in proprietary Drug Delivery Systems. These technological platforms include microspheres and liposomes. The company works in the complete development of these drugs, from the preclinical studies until the launch to the market. These specialties will be marketed either under own brands or through licenses. GP Pharm's main business areas are marketing of own products, licensing in & out and contract manufacturing, although we are open to other business collaborations such as R&D and commercial partnering, etc.

Located in Sant Quintí de Mediona, near Barcelona, the new production plant of **GP Pharm** has achieved EU GMP approval and started manufacturing operations, producing the first batches of own products and also for some contract manufacturing partners. Their facilities are also in process of being FDA GMP approved to different products. For further information about GP Pharm: website: [www.gp-pharm.com](http://www.gp-pharm.com)

### **About Lee's**

**Lee's Pharmaceutical Holdings Limited** is a research-based Hong Kong biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with 20 international companies and currently has 13 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee's Pharmaceutical: Website: [www.leespharm.com](http://www.leespharm.com)



---

**FOR IMMEDIATE RELEASE**

**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*